Voyager Life PLC - Option to acquire M3, Fundraise, Proposed RTO
Announcement provided by
Mendell Helium plc · MDH27/06/2024 10:19
27 June 2024
Voyager Life plc
("Voyager" or the "Company")
Option to acquire M3 Helium Corp.
Issue of Equity
Proposed reverse takeover
Voyager is pleased to announce that it has entered into an option agreement (the "Option") to acquire the entire issued share capital of M3 Helium Corp., ("M3 Helium"), a producer of helium based in
The exercise of the Option will constitute a reverse takeover pursuant to AQSE Rule 3.6 of the Access Rule Book and is subject to, inter alia, publication of an admission document (the "Admission Document").
Highlights
· M3 Helium is already producing helium and natural gas from its first well and has successfully tested four other wells as being economic to operate
· Through an arrangement with a local partner, M3 Helium has access to existing infrastructure to transport and process helium in large quantities (specifically a pipeline to a processing plant)
· The Directors believe that M3 Helium has the ability, subject to funding and availability of new leases, to scale up its projects to new drilling sites based on expected resource capacity from an independent resource report
· M3 Helium owns an existing modular hybrid plant to process and enrich helium - utilised in
The Company has conditionally raised
The proceeds of the Fundraise will be utilised to:
· fund the development of M3 Helium's operations;
· M3 Helium expects to drill a further well at Hugoton North Play;
· costs for the preparation of an Admission Document in connection with the proposed re-admission to trading on AQSE Growth Market; and
· general working capital purposes for the Company.
The Fundraise will be undertaken in two tranches. The first tranche of 6,576,456 New Ordinary Shares ("First Tranche") will utilise existing share authorities and will be issued pursuant to the Fundraise with admission of the First Tranche to trading on Aquis Stock Exchange AQSE Growth Market expected to occur on or around 4 July 2024 ("First Tranche Admission"). The second tranche of 22,239,150 New Ordinary Shares ("Second Tranche"), including the Warrants, will be issued and admitted to trading on Aquis Stock Exchange AQSE Growth Market ("Second Tranche Admission") subject to approval by Voyager's shareholders at a forthcoming general meeting to be convened shortly (the "General Meeting").
The Directors intend to dispose of Voyager's existing plant-based health and wellness operations following the Acquisition.
There is no certainty that the Option will be exercised, nor that the enlarged group will successfully complete its re-admission to trading on the AQSE Growth Market.
Overview of M3 Helium
M3 Helium owns economic interests in five wells in
M3 Helium operates in
Hugoton Field: North Play
The
The field's cumulative production is substantial, with over 30 trillion cubic feet of natural gas produced since being discovered. Additionally, it has yielded substantial quantities of natural gas liquids and helium.
M3 Helium's North Play potentially extends to 250 sections with recoverable gas, with each section being approximately 640 acres (one square mile). Production to date has indicated a helium content of 1.25 per cent., a concentration that compares very favourably to other parts of the
The north region of the field has been historically largely undeveloped because of the combination of high nitrogen content, which makes natural gas economically challenging, coupled with infrastructure costs. These economic impediments changed on 1 April 2024 when Scout Energy acquired the only existing pipeline thereby providing M3 Helium with a direct path to commercial sale, utilising Scout Energy's Jayhawk helium plant in
An independent resource report prepared by WSP for the benefit of M3 Helium on 25 January 2024 provided the following probabilistic contingent resource estimates*:
|
Unit |
P90 Low Estimate |
P50 Best Estimate |
P10 High Estimate |
Natural Gas |
Bcf |
787.7 |
1,068.9 |
1,442.2 |
Helium |
MMcf |
16,513.6 |
23,038.4 |
31,994.7 |
*The resource report has not been prepared to the standards of a competent person's report in line with the requirements for
Vertical wells in the North Play are forecast by M3 Helium to cost approximately
Gas production |
95 mcf/day |
Helium content |
1.25% |
Annual decline |
8% |
Helium sale price |
|
Natural gas price |
|
Royalties |
19% |
Processing fees |
20% |
*M3 Helium models a flat helium price in determining financial returns from its wells although most market commentators predict a rising price over the 30 year well life.
M3 Helium estimates that the average life of vertical wells in the Hugoton North Play is circa 30 years. Whilst, to date, it has solely drilled vertical wells, management's longer-term strategy is to drill horizontal wells at this location. Upfront costs would be higher at circa
Fort Dodge Prospect is in
The
Vertical wells in
Gas production |
300 mcf/day |
Helium content |
4.6% |
Annual decline |
10% |
Helium sale price |
|
Natural gas price |
|
Royalties |
20% |
Restructuring of M3 Helium
Prior to entering into the Option, M3 Helium underwent a restructuring whereby title to certain of its assets was transferred into the company in return for issuing shares to the asset owners. The purpose of the restructuring was to ensure that all assets were held by a single legal entity and so that Voyager was able to enter into the Option with M3 Helium. The Option will expire if it has not been exercised by Voyager by 30 September 2024.
Voyager's acquisition of M3 Helium (the "Acquisition") will be classified as a reverse takeover under Rule 3.6 of the AQSE Growth Market Access Rule Book and, consequently, exercising the Option will be subject to the publication of the Admission Document and re-admission to trading on the AQSE Growth Market.
Financial information on M3 Helium
M3 Helium was incorporated on 16 June 2023 and prepared its first unaudited accounts to the period ended 31 December 2023. In that period, it recorded total operating expenses of
M3 Helium has also provided Voyager with up to date unaudited financial information prepared on an interim basis to 31 May 2024. This reflects the ongoing development of its
M3 Helium presents its accounts in US GAAP but, following completion of the Acquisition and once it is a subsidiary of the Company, it will report in IFRS. There are certain differences in the two standards for companies in the natural resources industry including:
· Expense recognition: Under IFRS, expense recognition is generally principles-based. Expenses are recognised when it is probable that a decrease in future economic benefits related to a decrease in an asset or an increase in a liability has occurred and can be measured reliably. Under US GAAP, expense recognition is more rules-based and follows a matching principle, meaning expenses should be matched with the revenues they help to generate.
· Leases: Under IFRS all leases are recognised on the balance sheet (with some exceptions for short-term and low-value leases), with a right-of-use asset and corresponding lease liability. US GAAP applies more distinctions between finance leases and operating leases, affecting the pattern of expense recognition in the income statement.
· Exploration and evaluation (E&E) costs: Companies have the flexibility to either expense or capitalise E&E costs. If capitalised, they are classified as intangible or tangible assets and assessed for impairment when facts and circumstances suggest that the carrying amount may exceed recoverable amount. Under US GAAP, E&E costs are generally expensed as incurred but allows capitalisation of costs associated with successful exploration efforts, while unsuccessful efforts are expensed.
· Capitalisation Criteria: IFRS also provides a broader criteria for the capitalisation of development costs; specifically costs can be capitalised if it is probable that they will generate future economic benefits and the costs can be measured reliably.
· Impairment Reversal: Impairment testing is required when there are indicators of impairment. Assets are impaired if their carrying amount exceeds the recoverable amount. IFRS allows for the reversal of impairment losses (excluding goodwill) if conditions change whereas US GAAP does not. Under US GAAP, it is necessary to assess if the carrying amount is recoverable based on undiscounted cash flows. If not recoverable, the impairment loss is measured as the excess of carrying amount over fair value.
· Joint Arrangements: Under IFRS, joint arrangements are classified as either joint operations or joint ventures. Joint operations involve rights to assets and obligations for liabilities, with proportional consolidation. Joint ventures involve rights to net assets and are accounted for using the equity method. US GAAP also accounts for joint ventures using the equity method but proportional consolidation is generally not permitted.
The Directors expect there to be adjustments to M3 Helium's historic financial track record when it is consolidated with Voyager but they do not consider these changes to be significant to investors' understanding of the Acquisition or the prospects of the Company overall.
The Fundraising, Director Participation and Issue of Warrants
The Company has conditionally raised
The First Tranche of New Ordinary Shares will utilise existing share authorities with First Tranche Admission expected to occur on or around 4 July 2024. The Second Tranche, including the Warrants, will be issued and Second Tranche Admission will occur subject to approval by Voyager's shareholders at the General Meeting. The Company expects to publish and post a circular to shareholders and notice of General Meeting (the "Circular") shortly. A further announcement will be made when the Circular has been posted.
Eric Boyle, Non-executive Chairman, and Fetlar Capital Limited (a company controlled by Nick Tulloch, Chief Executive Officer and his spouse), each intend to invest
The Fundraise, which is not being underwritten, is conditional, inter alia, upon admission to trading on AQSE. The New Ordinary Shares will rank pari passu in all respects with the Ordinary Shares including the right to receive all dividends and other distributions declared, paid or made after the date of issue.
Previously, New Ordinary Shares issued by the Company have been eligible for Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) purposes providing tax benefits to certain investor groups. With its change in business activities, Voyager will apply to HMRC for clarification whether these tax efficient qualifications will remain in place following the Acquisition.
Use of Proceeds and Strategy
The Fundraise will raise proceeds of £864,468 for the Company which will be applied towards:
· the development of M3 Helium's operations;
· M3 Helium expects to drill a further well at Hugoton North Play;
· preparation of the Admission Document; and
· general working capital purposes.
The Company expects to exercise the Option on re-admission to trading on AQSE Growth Market of the enlarged group and, immediately following the Fundraise, will commence preparation of the Admission Document. The Company intends to make a loan facility of up to
The Loan Facility has been prepared on the basis of an arm's length commercial agreement between Voyager and M3 Helium for a term of up to one year. The Loan Facility and bears an interest rate of 6 per cent. per annum starting from the date on which the funds are received and ending upon the term date. The Loan Facility contains restrictions on M3 Helium taking on external finance and is structured to ensure it ranks in priority to M3 Helium's other obligations. Drawdowns under the Loan Facility must be for a specified purpose, namely the ongoing development of M3 Helium's business.
Voyager's existing health and wellness operations
Following the Acquisition, the Directors intend to dispose of Voyager's existing plant-based health and wellness operations. These comprise:
(i) Manufacturing facility in
(ii) E-commerce and wholesale operations based in
(iii) Three retail stores in
Although the Directors have concluded that the scale of these operations is not likely to be large enough in the short term to justify being a public company, there have been considerable successes in recent months. On 4 June 2024, Voyager announced that it had been successful in pitching for and winning a substantial new customer for its manufacturing division, VoyagerCann. terms with this customer are for a preliminary order for six product lines with an initial order value of up to
With these successes, and even taking account of the low valuations currently ascribed to CBD and cannabis companies at present, the Board believes that a disposal of these operations will be possible in the near term and, importantly, will not be a significant cash drain on the Company in the meantime. The Company's manufacturing, e-commerce and wholesale operations can be profitable without the burden of the expenses of being a public company and, despite challenges on the high street, market rents for at least two of Voyager's shops are now materially higher than the rent paid by the Company so transferring these leases in the short term is a realistic possibility.
Appointment of new director
Following completion of the Acquisition, it is intended that Paul Mendell, co-founder of M3 Helium will join the board of directors of Voyager.
Paul is an oil and gas producer and co-founder of two
A further announcement will be made in due course.
Admission
Application will be made for First Tranche to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market. First Tranche Admission is expected to occur at 8:00 am on or around 4 July 2024. Application will also be made for the Second Tranche to be admitted to trading on the Aquis Stock Exchange AQSE Growth Market with Second Tranche Admission expected to occur as soon as practicable following the approval of shareholders at the forthcoming General Meeting. The New Ordinary Shares will rank pari passu with the existing ordinary shares.
Total voting rights
Following First Tranche Admission, the Company's enlarged share capital will comprise 20,979,344 ordinary shares of
Warrants will be issued over 14,407,803 new Ordinary Shares pursuant to the Fundraise, and, in aggregate, 19,338,759 Warrants will be in issue following Second Tranche Admission.
The Directors of Voyager consider that the announcement contains sufficient information about M3 Helium to provide a properly informed basis for assessing its financial position. M3 Helium has also advised that it will regularly update Voyager to enable Voyager to keep the market informed without delay of any developments concerning M3 Helium that may require an announcement to be released by Voyager.
Nick Tulloch, Chief Executive Officer and Founder of Voyager, said: "Investors might understandably be surprised by our decision to restructure our business as a helium producer but, although the change may seem sudden, it is the product of a considered plan. Eric Boyle and I have known Paul Mendell, founder of M3 Helium, for many years. We worked together at Highlands Natural Resources and Paul was one of Voyager's first directors. Prior to founding Voyager, we looked at a different helium opportunity in
"In the past two years, it is apparent that investors have developed a degree of caution around cannabis and CBD companies. The sector has been beset by disappointments and share prices, including our own, have underperformed. Conversely, helium opportunities have become highly popular as evidenced by the success of recent fundraisings, again including our own. We may reflect that it is ironic that we are switching horses just as our CBD business reaches new levels of success but we have a responsibility to our shareholders to act in their best interests. A health & wellness manufacturer and e-commerce business like Voyager may be better suited as a private company or being part of a larger entity whereas our public company can support a fast-growing natural resources opportunity.
"M3 Helium offers several significant benefits. With proven geology in one of the
"The option structure announced today gives the two companies the ability to work together on further investments in
This announcement contains inside information for the purposes of the
ENDS
Enquiries:
Voyager Life plc
Nick Tulloch, CEO
|
Tel: +44 (0) 1738 317 693
|
Cairn Financial Advisers LLP (AQSE Corporate Adviser)
Ludovico Lazzaretti/Liam Murray
|
Tel: +44 (0) 20 7213 0880 |
SI Capital Limited (Broker)
Nick Emerson/Nick Briers |
Tel: +44 (0) 1483 413500 |
Stanford Capital Partners LLP (Broker)
Patrick Claridge/Bob Pountney
|
Tel: +44 (0) 203 3650 3650/51
|
FORWARD LOOKING STATEMENTS
This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could" or "similar" expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.